Hikma calls off Injectables sale
This article was originally published in Scrip
Executive Summary
Hikma has decided against selling off its global Injectables business, which analysts had valued at up to $2.2 billion (scripintelligence.com, 4 March 2013). The Jordanian headquartered company Hikma had been conducting a strategic review of options following significant interest in the unit apparently sparked Mylan's $1.6 billion acquisition of Strides Arcolab's similar business Agila Specialities earlier this year. Companies such as Pfizer and Novartis were rumored to have been disappointed bidders for Agila (scripintelligence.com, 28 February 2012).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.